Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN study)

Next Previous
Trial Profile

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN study)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esaxerenone (Primary)
  • Indications Diabetic nephropathies
  • Focus Registrational; Therapeutic Use
  • Acronyms ESAX-DN study
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 08 Nov 2019 According to a Daiichi Sankyo Company media release, results were presented during Kidney Week 2019, the annual meeting of the American Society of Nephrology,
    • 08 Nov 2019 Results published in the Daiichi Sankyo Company Media Release
    • 07 Nov 2019 Results presented in the Exelixis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top